Market Indices
Sector Heatmap
CLDX — Celldex Therapeutics, Inc
NasdaqCelldex Therapeutics, Inc
- O
- 32.26
- H
- 32.54
- L
- 30.98
- V
- 2.36M
CLDX — Latest News & Headlines
19 StoriesCelldex Therapeutics (Nasdaq:CLDX) - Stock Analysis - Simply Wall Street
Celldex Therapeutics (Nasdaq:CLDX) - Stock Analysis Simply Wall Street
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success? - Yahoo Finance
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success? Yahoo Finance
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’ - Stocktwits
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’ Stocktwits
Celldex stock falls after hives trial data (CLDX:NASDAQ) - Seeking Alpha
Celldex stock falls after hives trial data (CLDX:NASDAQ) Seeking Alpha
Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results | CLDX Stock News - Quiver Quantitative
Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results | CLDX Stock News Quiver Quantitative
(CLDX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
(CLDX) as a Liquidity Pulse for Institutional Tactics Stock Traders Daily
Canaccord Genuity Sticks to Their Buy Rating for Celldex (CLDX) - The Globe and Mail
Canaccord Genuity Sticks to Their Buy Rating for Celldex (CLDX) The Globe and Mail
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About? Kalkine Media
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64 - Moomoo
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64 Moomoo
Why is Celldex Therapeutics stock plummeting today? - Investing.com
Why is Celldex Therapeutics stock plummeting today? Investing.com
Did Phase 3 Trial Success Just Shift Celldex Therapeutics' (CLDX) Investment Narrative? - Simply Wall Street
Did Phase 3 Trial Success Just Shift Celldex Therapeutics' (CLDX) Investment Narrative? Simply Wall Street
Leerink Partners maintains Outperform rating on Celldex Therapeutics, $88 price target - TradingView
Leerink Partners maintains Outperform rating on Celldex Therapeutics, $88 price target TradingView
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - Zacks Investment Research
4 Biotech Stocks With Key Clinical Readouts Expected This Fall Zacks Investment Research
Celldex Therapeutics stock gains as analysts target USD 56.42 - AD HOC NEWS
Celldex Therapeutics stock gains as analysts target USD 56.42 AD HOC NEWS
Is Celldex Therapeutics (CLDX) Fully Priced After Its Phase 3 Win? - Simply Wall Street
Is Celldex Therapeutics (CLDX) Fully Priced After Its Phase 3 Win? Simply Wall Street
Why is Celldex Therapeutics stock sliding today? By Investing.com - Investing.com UK
Why is Celldex Therapeutics stock sliding today? By Investing.com Investing.com UK
Celldex Therapeutics (CLDX) Shares Moved, So What Is Driving Attention Today? - Simply Wall Street
Celldex Therapeutics (CLDX) Shares Moved, So What Is Driving Attention Today? Simply Wall Street
Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings By Investing.com - Investing.com Australia
Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings By Investing.com Investing.com Australia
Why Celldex Shares Are Suddenly Losing Altitude - TipRanks
Why Celldex Shares Are Suddenly Losing Altitude TipRanks